The spreading and colonization of
tumor cells require their migration to metastatic sites via blood vessels. To penetrate blood-vessel walls, cells, including malignant ones, must recognize and associate with the sub-endothelium extracellular matrix (ECM) and its
glycoproteins. Recognition of ECM-
glycoproteins, such as
fibronectin (FN) and
vitronectin (VN), is mediated by
integrin receptors expressed on various cell types, including platelets, leukocytes and
tumor cells. The
Arg-Gly-Asp (RGD)-containing
peptide, a major adhesive
ligand of ECM, is present in various plasma and matrix
glycoproteins, such as FN and VN. Non-peptidic mimetics of RGD, consisting of carboxylate and
guanidinium groups of Asp and Arg divided by a linear atom spacer, express a high affinity for the alpha IIb-
beta 3 integrin and inhibit platelet aggregation. Herein, the ability of RGD mimetics to inhibit adhesive interactions between
tumor cells and RGD, and
tumor progression in vivo, was examined. RGD-containing
peptides and the RGD mimetic, compound
SF-6,5, but not the
Arg-Gly-Glu (
RGE) peptide or the corresponding mimetic, specifically inhibited B16-F10
melanoma cell adhesion to immobilized VN and FN. Daily administration in vivo of
SF-6,5 to mice inhibited the formation of B16-F10 colonies in experimental and spontaneous models of
metastases. Moreover,
SF-6,5 could prevent mouse death caused by massive colonization of
tumor cells in the lungs. The
therapeutic effect of RGD-containing
peptides on
tumor metastasis formation was marginal, probably due to the small amounts used, and its susceptibility to proteolysis in situ. Thus, non-peptidic mimetics of small adhesive
epitopes may provide a novel therapeutic tool to prevent an adverse pathological event involving
integrin-dependent cell-cell and cell-ECM interactions.